Abstract
The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma. The major dose-limiting toxicity was granulocytopenia. There was one toxic death from sepsis. Central nervous system and renal toxicity occurred infrequently, perhaps as a result of the continuous-infusion schedule. This regimen is being evaluated further in advanced disease, the adjuvant setting, and in combination with bone marrow colony-stimulating factors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 41-49 |
| Number of pages | 9 |
| Journal | Seminars in oncology |
| Volume | 17 |
| Issue number | 2 SUPPL. 4 |
| State | Published - Apr 1990 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology